Literature DB >> 17124508

A novel MASH1 enhancer with N-myc and CREB-binding sites is active in neuroblastoma.

F Watt1, R Watanabe, W Yang, N Agren, Y Arvidsson, K Funa.   

Abstract

Neuroblastoma is one of the most common solid tumors in childhood. With the aim of developing a targeting vector for neuroblastoma, we cloned and characterized an enhancer in the 5'-flanking regions of the MASH1 gene by a random-trap method from a 36 kb cosmid DNA. The enhancer-containing clone was identified by the expression of GFP when transfected into neuroblastoma cell lines. The enhancer-luciferase activity is higher in neuroblastoma cell lines, IMR32, BE2 and SH-SY5Y, compared with those in non-neuroblastoma cell lines, U1242 glioma, N417 small cell lung cancer and EOMA hemangioma. The core enhancer was determined within a 0.2 kb fragment, yielding three- to fourfold higher activity than that of the MASH1 promoter alone in IMR32 and BE2. This area possesses GATA- and CREB-binding sites, as well as the E-box. EMSA on this area demonstrated that CREB/ATF could bind the DNA. Chromatin immunoprecipitation assay revealed that N-myc, CREB, and co-activators CBP and PCAF, but not HDAC1, are bound to the core enhancer at the same time as the co-activators and N-myc bind to the promoter. This supports the idea that the commonly overexpressed genes HASH1 and N-myc are regulated in concert, confirming their importance as prognostic markers or targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124508     DOI: 10.1038/sj.cgt.7701012

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  6 in total

1.  Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.

Authors:  Tomomasa Hiramatsu; Jyoji Yoshizawa; Kazuaki Miyaguni; Tetsuro Sugihara; Atsushi Harada; Sayuri Kaji; Goki Uchida; Daisuke Kanamori; Yuji Baba; Shuichi Ashizuka; Takao Ohki
Journal:  Pediatr Surg Int       Date:  2018-02-08       Impact factor: 1.827

2.  Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Authors:  Chuan Jin; Di Yu; Matko Čančer; Berith Nilsson; Justyna Leja; Magnus Essand
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

Review 3.  LIM-domain-only proteins in cancer.

Authors:  Jacqueline M Matthews; Krystal Lester; Soumya Joseph; David J Curtis
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

4.  Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1.

Authors:  Eriko Isogai; Miki Ohira; Toshinori Ozaki; Shigeyuki Oba; Yohko Nakamura; Akira Nakagawara
Journal:  PLoS One       Date:  2011-05-05       Impact factor: 3.240

5.  MYCN induces neuroblastoma in primary neural crest cells.

Authors:  R R Olsen; J H Otero; J García-López; K Wallace; D Finkelstein; J E Rehg; Z Yin; Y-D Wang; K W Freeman
Journal:  Oncogene       Date:  2017-05-01       Impact factor: 9.867

6.  Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis.

Authors:  Bret C Mobley; Minjae Kwon; Bradley R Kraemer; F Edward Hickman; Jingbo Qiao; Dai H Chung; Bruce D Carter
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.